Comparative Pharmacology
Head-to-head clinical analysis: ENDURON versus HYDROCHLOROTHIAZIDE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURON versus HYDROCHLOROTHIAZIDE INTENSOL.
ENDURON vs HYDROCHLOROTHIAZIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing water excretion.
Inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and chloride reabsorption and increasing water excretion.
Oral, 2.5–5 mg once daily. Maximum dose 10 mg/day.
25-100 mg orally once daily or in divided doses. Titrate based on response; maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 24-48 hours (mean 36 hours); prolonged in renal impairment or heart failure, allowing once-daily dosing.
Terminal half-life 6–15 hours (mean ~10 hours); prolonged in renal impairment (creatinine clearance <30 mL/min) and elderly.
Primarily renal (approximately 50-70% as unchanged drug); biliary/fecal (15-30%); dose adjustment required in renal impairment (CrCl <30 mL/min).
Primarily renal (≥95% as unchanged drug); negligible biliary/fecal elimination (<5%).
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic